Resverlogix Announces Annual General Meeting Voting Results
TSX Exchange Symbol: RVX
CALGARY, Oct. 8, 2014 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual meeting of shareholders held on October 8, 2014, each of the five nominees proposed as a director and listed in its management information circular dated August 25, 2014 (the "Information Circular") were elected as directors. Proxy voting results for each nominee are set out below:
Votes For |
Votes Withheld |
% For |
% Withheld |
|
Donald J. McCaffrey |
19,598,577 |
272,713 |
(98.63%) |
(1.37%) |
Peter Johann |
19,735,454 |
135,836 |
(99.32%) |
(0.68%) |
Kelly McNeill |
19,598,354 |
272,936 |
(98.63%) |
(1.37%) |
Kenneth Zuerblis |
19,745,389 |
125,901 |
(99.37%) |
(0.63%) |
Eldon Smith |
19,618,789 |
252,501 |
(98.73%) |
(1.27%) |
About Resverlogix
Resverlogix Corp. (TSX:RVX) is a clinical stage cardiovascular company developing compounds involving a therapeutic increase in ApoA-1. RVX-208 is a first in-class small molecule for the treatment of atherosclerosis and other chronic diseases such as Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX:RVX). For further information, please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.
Company Contacts: |
|
Donald J. McCaffrey |
Sarah Zapotichny |
President and CEO |
Director, Investor Relations |
Resverlogix Corp. |
Resverlogix Corp. |
Phone: 403-254-9252 |
Phone: 403-254-9252 |
Email: [email protected] |
Email: [email protected] |
SOURCE: Resverlogix Corp.
Share this article